Herrera GNE, Gómez PG

Language: Spanish
References: 17
Page: 206-209
PDF size: 179.80 Kb.

ABSTRACT

Melanoma possesses the ability to elicit a profound immune response, as demonstrated by spontaneous regression of primary and metastatic disease. However, most immune therapies fail suggesting the development of immune suppressive mechanism. Regulatory T cells (Tregs) are an immunosuppressive population of T cells expressing high levels of CD25+Foxp3+, constituting 2-3% of the total CD4+ T cell population. Although the precise mechanism of Tregs cell-induced immune suppression is not understood, Tregs cells act in part by secreting immunosuppressive cytokines and suppressing the activation and proliferation of T cells, loosing with this the anti-tumoral response. For this reason we have called these cells “the bodyguards of melanoma cells”.

REFERENCES

1. Hsu MY, Meier F, Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002;70(9-10):522-536.

2. Ilkovitch D, Lopez DM. Immune modulation by melanomaderived factors. Exp Dermatol 2008;17(12):977-985.

3. Camisaschi C, Casati C, Rini F, Perego M, et al. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 2010;184(11):6545-6551.

4. Oble DA, Loewe R, Yu P, Mihm MC Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009;9:3.

5. Vásquez MI, Meraz RMA, Villanueva LCG, Magaña M, et al. ATP-binding cassette transporter ABCB5 gene is expressed with variability in malignant melanoma. Actas Dermosifiliogr 2010;101(4):341-348.

6. Flores A. Tesis de licenciatura, 2010.

7. Dudley ME, Yang JC, Sherry R, Hughes MS, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26(32):5233-5239.

8. Lázár-Molnár E, Hegyesi H, Tóth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000;12(6):547-554.

9. Sica A, Larghi P, Mancino A, Rubino L, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008;18(5):349-355.

10. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7(3):211-217.

11. Ghassabeh GH, De Baetselier P, Brys L, Noël W, et al. Identification of a common gene signature for type II cytokineassociated myeloid cells elicited in vivo in different pathologic conditions. Blood 2006;108(2):575-583.

12. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001;193(11):1303-1310.

13. González Parias JL, Duque Giraldo VE, Velásquez Lopera MM. Foxp3: master gene controlling the development and function of regulatory cells. Immunol Rev 2010;29(2):74-84.

14. Baumgartner J, Wilson C, Palmer B, Richter D, et al. Melanoma induces immunosuppression by up-regulating Foxp3(+) regulatory T cells. J Surg Res 2007;141(1):72-77.

15. Viguier M, Lemaître F, Verola O, Cho MS, et al. Foxp3 expressing CD4+CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173(2):1444-1453.

16. Mahnke K, Schönfeld K, Fondel S, Ring S, et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007;120(12):2723-2733.

17. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008;333(1- 2):167-179.